Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

NEW YORK--(BUSINESS WIRE) December 29, 2022 -- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials